Clinical evidence suggests that sacubitril/valsartan further reduces the risk of HF hospitalization, cardiovascular mortality, and all other causes of mortality in patients with HF who can tolerate angiotensin-converting enzyme inhibitors (ACEI) or ARBs, but also has a better safety and tolerability profile (15). The gene discussed is ACE; the disease is hydrops fetalis.